Literature DB >> 11740689

Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation.

J T Horan1, C W Francis.   

Abstract

Disseminated intravascular coagulation (DIC) is characterized by activation of hemostasis and fibrinolysis resulting in the formation of thrombin and plasmin, and the characteristic effects of these enzymes on plasma fibrinogen can be useful in diagnosis. Thrombin cleaves fibrinopeptides from fibrinogen, forming fibrin monomer that rapidly polymerizes to form a clot. Small amounts can circulate in plasma as "soluble fibrin," which may have a complex composition and include fibrinogen and a variable amount of cross-linking. Plasmic degradation of cross-linked fibrin forms a heterogeneous group of degradation products reactive in assays for D-dimer, and their levels provide a measure of the amount of fibrin formation and lysis. Caution should be exercised in comparing quantitative results using different assays because of problems with standardization and variable reactivity with different molecular forms. Marked elevations of fibrin(ogen) degradation products are a constant finding in experimental animal models of DIC. In human models of DIC resulting from endotoxin infusion, D-dimer is elevated early and high levels persist, reflecting lysis of microvascular fibrin deposits. Elevated levels of D-dimer and soluble fibrin are very sensitive for the diagnosis of DIC, and a normal level has a high negative predictive value. Serial monitoring of soluble fibrin or D-dimer assays may be of value in evaluating the response to therapy and possibly in identifying at-risk patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11740689     DOI: 10.1055/s-2001-18870

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  12 in total

1.  A Correlation of the Platelet Count with D-Dimer Levels as an Indicator for Component Therapy in Children with Dengue Hemorrhagic Fever.

Authors:  Arthi Sridhar; B M Sunil Kumar; Aarathi Rau; A T K Rau
Journal:  Indian J Hematol Blood Transfus       Date:  2016-05-24       Impact factor: 0.900

2.  Sulfated, low-molecular-weight lignins are potent inhibitorsof plasmin, in addition to thrombin and factor Xa: Novel opportunity for controlling complex pathologies.

Authors:  Brian L Henry; May Abdel Aziz; Qibing Zhou; Umesh R Desai
Journal:  Thromb Haemost       Date:  2009-12-18       Impact factor: 5.249

3.  In vitro and in vivo evaluation of microporous chitosan hydrogel/nanofibrin composite bandage for skin tissue regeneration.

Authors:  P T Sudheesh Kumar; N Mincy Raj; G Praveen; Krishna Prasad Chennazhi; Shantikumar V Nair; R Jayakumar
Journal:  Tissue Eng Part A       Date:  2012-10-10       Impact factor: 3.845

Review 4.  Fibrin Formation, Structure and Properties.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Subcell Biochem       Date:  2017

5.  The efficacy and safety of edoxaban versus warfarin in preventing clinical events in atrial fibrillation: A systematic review and meta-analysis.

Authors:  Xiangwen Liang; Wenchao Xie; Zhihai Lin; Ming Liu
Journal:  Anatol J Cardiol       Date:  2021-02       Impact factor: 1.596

6.  Elevated levels of soluble fibrin in patients with venous thromboembolism.

Authors:  Akihiro Tsuji; Hideo Wada; Takeshi Matsumoto; Yasunori Abe; Satoshi Ota; Norikazu Yamada; Takashi Sugiyama; Akihiro Sudo; Katsuya Onishi; Kaname Nakatani; Atsumasa Uchida; Masaaki Ito; Koji Suzuki; Tsutomu Nobori
Journal:  Int J Hematol       Date:  2008-10-04       Impact factor: 2.490

7.  Disseminated intravascular coagulation: current concepts.

Authors:  R Kumar; V Gupta
Journal:  Indian J Pediatr       Date:  2008-08-21       Impact factor: 1.967

8.  Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis.

Authors:  Jordan Kountchev; Klaudija Bijuklic; Romuald Bellmann; Christian J Wiedermann; Michael Joannidis
Journal:  Crit Care       Date:  2005-09-19       Impact factor: 9.097

9.  In Vitro and In Vivo Evaluation of Commercially Available Fibrin Gel as a Carrier of Alendronate for Bone Tissue Engineering.

Authors:  Beom Su Kim; Feride Shkembi; Jun Lee
Journal:  Biomed Res Int       Date:  2017-01-22       Impact factor: 3.411

10.  Trousseau's syndrome in association with cholangiocarcinoma: positive tests for coagulation factors and anticardiolipin antibody.

Authors:  Jeong Won Jang; Chang Dong Yeo; Jin Dong Kim; Si Hyun Bae; Jong Young Choi; Eun Sun Jung; Sung Eun Rha; Jae Young Byun; Seung Kew Yoon
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.